Historical Valuation
TScan Therapeutics Inc (TCRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.46 is considered Undervalued compared with the five-year average of -2.48. The fair price of TScan Therapeutics Inc (TCRX) is between 1.27 to 2.36 according to relative valuation methord. Compared to the current price of 1.21 USD , TScan Therapeutics Inc is Undervalued By 4.63%.
Relative Value
Fair Zone
1.27-2.36
Current Price：1.21
4.63%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
TScan Therapeutics Inc (TCRX) has a current Price-to-Book (P/B) ratio of 0.40. Compared to its 3-year average P/B ratio of 1.06 , the current P/B ratio is approximately -62.17% higher. Relative to its 5-year average P/B ratio of 0.88, the current P/B ratio is about -54.33% higher. TScan Therapeutics Inc (TCRX) has a Forward Free Cash Flow (FCF) yield of approximately -234.70%. Compared to its 3-year average FCF yield of -82.50%, the current FCF yield is approximately 184.49% lower. Relative to its 5-year average FCF yield of -79.50% , the current FCF yield is about 195.21% lower.
P/B
Median3y
1.06
Median5y
0.88
FCF Yield
Median3y
-82.50
Median5y
-79.50
Competitors Valuation Multiple
AI Analysis for TCRX
The average P/S ratio for TCRX competitors is 1.95, providing a benchmark for relative valuation. TScan Therapeutics Inc Corp (TCRX.O) exhibits a P/S ratio of 8.46, which is 334.79% above the industry average. Given its robust revenue growth of 139.37%, this premium appears sustainable.
Performance Decomposition
AI Analysis for TCRX
1Y
3Y
5Y
Market capitalization of TCRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TCRX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TCRX currently overvalued or undervalued?
TScan Therapeutics Inc (TCRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.46 is considered Undervalued compared with the five-year average of -2.48. The fair price of TScan Therapeutics Inc (TCRX) is between 1.27 to 2.36 according to relative valuation methord. Compared to the current price of 1.21 USD , TScan Therapeutics Inc is Undervalued By 4.63% .
What is TScan Therapeutics Inc (TCRX) fair value?
TCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of TScan Therapeutics Inc (TCRX) is between 1.27 to 2.36 according to relative valuation methord.
How does TCRX's valuation metrics compare to the industry average?
The average P/S ratio for TCRX's competitors is 1.95, providing a benchmark for relative valuation. TScan Therapeutics Inc Corp (TCRX) exhibits a P/S ratio of 8.46, which is 334.79% above the industry average. Given its robust revenue growth of 139.37%, this premium appears sustainable.
What is the current P/B ratio for TScan Therapeutics Inc (TCRX) as of Jan 10 2026?
As of Jan 10 2026, TScan Therapeutics Inc (TCRX) has a P/B ratio of 0.40. This indicates that the market values TCRX at 0.40 times its book value.
What is the current FCF Yield for TScan Therapeutics Inc (TCRX) as of Jan 10 2026?
As of Jan 10 2026, TScan Therapeutics Inc (TCRX) has a FCF Yield of -234.70%. This means that for every dollar of TScan Therapeutics Inc’s market capitalization, the company generates -234.70 cents in free cash flow.
What is the current Forward P/E ratio for TScan Therapeutics Inc (TCRX) as of Jan 10 2026?
As of Jan 10 2026, TScan Therapeutics Inc (TCRX) has a Forward P/E ratio of -1.13. This means the market is willing to pay $-1.13 for every dollar of TScan Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for TScan Therapeutics Inc (TCRX) as of Jan 10 2026?
As of Jan 10 2026, TScan Therapeutics Inc (TCRX) has a Forward P/S ratio of 8.46. This means the market is valuing TCRX at $8.46 for every dollar of expected revenue over the next 12 months.